Gsk (GLAXF) Times Interest Earned (2009 - 2026)
Gsk (GLAXF) recorded quarterly Times Interest Earned of -$13.73 in Q1 2026, down 775.01% quarter-over-quarter from -$1.57 in Q4 2025, and little changed on a YoY basis from -$13.78 in Q1 2025.
Gsk (GLAXF) Times Interest Earned (2009 - 2026) Analysis & Trends
Gsk's Times Interest Earned history runs 18 years deep, the most recent figure standing at -$13.73 for Q1 2026.
- In Q1 2026, Times Interest Earned changed 0.38% year-over-year to -$13.73; the TTM figure through Mar 2026 stood at -$6.6 (down 7.29% YoY), while the FY2025 annual figure was $11.32, up 88.26% from the prior year.
- Times Interest Earned was -$13.73 for Q1 2026 at Gsk, down from -$1.57 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.21 in Q3 2024 to a low of -$15.53 in Q3 2025.
- Historically, Times Interest Earned has averaged -$8.47 across 5 years, with a median of -$9.46 in 2024.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned surged 88.69% in 2024, then sank 1181.59% in 2025.
- A 5-year view of Times Interest Earned shows it stood at -$3.84 in 2022, then slumped by 38.91% to -$5.33 in 2023, then rose by 12.09% to -$4.69 in 2024, then soared by 66.52% to -$1.57 in 2025, then plunged by 775.01% to -$13.73 in 2026.
- The last three Times Interest Earned figures came in at -$13.73 (Q1 2026), -$1.57 (Q4 2025), and -$15.53 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Gsk | - | - | 7.76 Bn | -13.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.73 |
| Dec 31, 2025 | -1.57 |
| Sep 30, 2025 | -15.53 |
| Jun 30, 2025 | -10.99 |
| Mar 31, 2025 | -13.68 |
| Dec 31, 2024 | -4.69 |
| Sep 30, 2024 | -1.21 |
| Jun 30, 2024 | -9.46 |
| Mar 31, 2024 | -8.98 |
| Dec 31, 2023 | -5.33 |
| Sep 30, 2023 | -10.71 |
| Jun 30, 2023 | -11.57 |
| Mar 31, 2023 | -10.26 |
| Dec 31, 2022 | -3.84 |
| Sep 30, 2022 | -5.96 |
| Jun 30, 2022 | -5.30 |
| Mar 31, 2022 | -11.19 |
| Dec 31, 2021 | -0.64 |
| Sep 30, 2021 | -7.08 |
| Jun 30, 2021 | -6.75 |